Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Glass Lewis recommended voting for all three incumbent director nominees and against the dissident slate from DOMA Perpetual Capital Management at the 2026 Annual Meeting.

• The board's 5x30 strategy aims to deliver substantial shareholder value by 2030, with recent returns cited as evidence of progress.

• New pipeline products, PCRX-201 and PCRX-2002, are in Phase 2 and expected to contribute to growth beyond 2030.

• The company maintains a strong IP position with 21 Orange Book-listed patents across two families.

• Forward-looking statements highlight ongoing product development, market expansion, and risk factors impacting future results.

Voting matters and shareholder proposals

• Stockholders are urged to vote for the three incumbent director nominees and disregard any proxy cards from DOMA.

• Glass Lewis found DOMA's alternative strategy and nominees lacking in necessary skills and alignment with shareholder interests.

Board of directors and corporate governance

• The board is described as well-balanced and mostly refreshed, supporting the current CEO's strategic plan.

• Glass Lewis endorsed the incumbent board's risk oversight and disclosure practices as meeting industry standards.